XORTX Therapeutics announces Health Canada clinical trial filing for gout drug XRx‑026
XORTX Therapeutics said it will submit a Clinical Trial Application to Health Canada for its XRx‑026 gout program, which will support the first part of its two‑part XRX‑OXY‑102 study. The company said the Canadian filing should speed delivery of data for a future U.S. New Drug Application. Co‑CEO Dr. Allen Davidoff noted that the filing could improve execution efficiency and increase the program’s value, and the firm reported heightened interest from potential commercialization partners, though no agreements have been signed.
Why it matters
The announcement sent XORTX shares up 22.16% in after‑hours trading, indicating strong short‑term market reaction to the regulatory milestone. The stock also rose about 16.7% in regular trading as traders priced in the accelerated development path.
Key facts
- 1XORTX plans to file a Clinical Trial Application with Health Canada for its XRx‑026 gout program. markets.businessinsider.com
- 2The CTA filing supports the first part of the two‑part XRX‑OXY‑102 clinical study of the proprietary XORLO™ formulation. markets.businessinsider.com
- 3Co‑CEO Dr. Allen Davidoff said the Health Canada filing is expected to enable more efficient clinical plan execution. markets.businessinsider.com
- 4XORTX has received increased inquiries from potential commercialization partners but has not entered any agreement. markets.businessinsider.com
- 5Shares climbed 22.16% to $2.26 in after‑hours trading following the announcement. benzinga.com
- 6The company’s market capitalization is approximately $3.35 million. benzinga.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.